Navigation Links
OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Date:2/15/2008

p> not manifested disease progression and approximately 60 percent of

patients remain alive in both arms. Median survival has not been

reached in either arm. These data compare favorably with published

results documenting median survivals of approximately 10 months.

- Reduction in pain or analgesic use was achieved in 50 percent or more

of patients entering the study with pain: Reductions in pain or

analgesic use were seen in 50 percent of evaluable patients treated

with mitoxantrone and in 67 percent of evaluable patients retreated

with docetaxel. These data compare favorably to the 22-35 percent of

patients receiving first-line chemotherapy who reported reduction in

pain in the TAX 327 study published in the New England Journal of

Medicine on October 7, 2004.

This Phase 2 study was designed as an open-label, randomized, multicenter study evaluating weekly administration of OGX-011 in combination with second-line chemotherapy in patients with metastatic hormone refractory prostate cancer who were previously treated with a minimum of 2 cycles of docetaxel-based first-line chemotherapy. Patients in this study represented a poor prognostic population due to rapid disease progression after completing first-line docetaxel therapy with a median of 0.7 months in the mitoxantrone treated group or 2.1 months in the docetaxel retreated group. Because OGX-011 has been shown to enhance chemotherapy and reverse chemotherapy resistance in preclinical in vitro and in vivo models, the aim of this study was to assess the effect of OGX-011 in combination with either mitoxantrone or docetaxel retreatment as second-line chemotherapy. Phase 3 studies are planned utilizing chemotherapy plus OGX-011 as second-line therapy in patients progressing after a first-line docetaxel regimen.

"These data show that the combination of OGX-011 with docetaxel or mitoxantrone may
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... Sterlitech is proud to debut its multi-line, ... 2015 AMTA Membrane Technology Conference in Orlando. This ... of engineering and customer feedback, which has resulted in ... applications across an array of disciplines. It is ... needs of researchers and engineers alike and is ideal ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... November 1, 2011 - Listed companies to present ... 30 - December 2 Elsevier Business Intelligence ... to Watch list. The list delivers projects and companies with ... growth through investments in deals. This year,s list includes ...
... Colo., Oct. 31, 2011 Azantis launches today AstaKrill™ ... Azantis , a leading krill oil manufacturer, markets AstaKrill to ... antioxidant that gives krill its distinct red color. The astaxanthin ... in other krill oils currently on the market. ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Opportunity Assessment and Market Forecasts to ... Spinal Implants - ...
Cached Biology Technology:Windhover Announces the "Top Biopharma Projects to Watch" 2Windhover Announces the "Top Biopharma Projects to Watch" 3AstaKrill™ the Best Krill Oil Boosts Astaxanthin 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... SALT LAKE CITY -- Climate change spells trouble ... mountains, coastal forests and relatively small areas and ... habitat loss, disease and competition among species. That ... 200 scientific studies relevant to the topic. The review ...
... To maintain power, oil-rich governments often lean on their ... damage their companies, efficiency and raise prices for the ... Mark Thurber. The state-owned oil companies, like Saudi ... control 73 percent of the world,s oil reserves, dwarfing ...
... NY, February 15, 2012Therapeutic cancer vaccines, which stimulate ... cancer cells, are being used in combination with ... several illuminating articles in Cancer Biotherapy and ... Liebert, Inc. ( http://www.liebertpub.com ). These articles are ...
Cached Biology News:Climate change threatens tropical birds 2Climate change threatens tropical birds 3Climate change threatens tropical birds 4Climate change threatens tropical birds 5Book examines state-owned oil firms, prices and pollution 2Book examines state-owned oil firms, prices and pollution 3Promising early results with therapeutic cancer vaccines 2
...
... Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
... The Polymerase gene from Thermus ... expressed in E. coli, then highly ... It is used in the amplification ... PCR. The quality of the Taq ...
... iTaq DNA polymerase is an ... for both conventional and real-time ... supplied at a concentration of ... includes 5,000 units polymerase, 25 ...
Biology Products: